John Dunn

Founded in 2004, Biogen Idec New Ventures is the corporate venture group of Biogen Idec, Inc. In 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen Idec, Inc. (NASDAQ: BIIB)

Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA.

Agility Clinical, Inc. operates as a specialty consulting and clinical research organization. It offers project management services, including project feasibility, study budget and timeline management, study tracking reports, risk assessment, mitigation, and vendor management; clinical operations services, such as investigator selection, regulatory document collection and submission, TMF set up and maintenance, clinical monitoring, and site management; and data management services, which include database design and validation, data cleaning, and EDC. The company was founded by Ellen Morgan and David F. Hale in April 2012 and is headquartered in Carlsbad, CA.

IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA.

Acer Therapeutics, Inc. develops therapeutics for the treatment of orphan diseases. Its current pipeline consists of two late-stage clinical products: ACER-002 for vascular Ehlers-Danlos Syndrome (vEDS), and ACER-001 for Maple Syrup Urine Disease (MSUD). The company was founded by Chris Schelling and is headquartered in Cambridge, MA.

Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX.